Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (551-560 of 652) with videos related to

Pageof 66
Sort By:
Blood Cancer Journal|February 15, 2020
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myelomaMeletios A Dimopoulos, Andrzej J Jakubowiak, Philip L McCarthy, et al.
Leukemia & Lymphoma|October 3, 2025
Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX studyNizar J Bahlis, Jeffrey Zonder, Lionel Karlin, et al.
Haematologica|July 11, 2015
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myelomaJesus F San Miguel, Katja C Weisel, Kevin W Song, et al.
The New England Journal of Medicine|August 30, 2008
Bortezomib plus melphalan and prednisone for initial treatment of multiple myelomaJesús F San Miguel, Rudolf Schlag, Nuriet K Khuageva, et al.
European Journal of Haematology|March 4, 2011
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myelomaMichel Delforge, Evangelos Terpos, Paul G Richardson, et al.
British Journal of Haematology|May 29, 2010
Monoclonal gammopathy of undetermined significance: a consensus statementJames R Berenson, Kenneth C Anderson, Robert A Audell, et al.
Blood|July 22, 2016
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myelomaHervé Avet-Loiseau, Rafael Fonseca, David Siegel, et al.
American Journal of Hematology|April 22, 2011
No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 yearsEfstathios Kastritis, Marie-Christine Kyrtsonis, Evdoxia Hatjiharissi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2023
Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's MacroglobulinemiaChristian Buske, Meletios A Dimopoulos, Alexander Grunenberg, et al.
British Journal of Haematology|June 28, 2017
Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trialJesús F San-Miguel, Vania T M Hungria, Sung-Soo Yoon, et al.
Pageof 66

Showing results (551-560 of 652) with videos related to

Sort By:
Pageof 66
Blood Cancer Journal|February 15, 2020
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myelomaMeletios A Dimopoulos, Andrzej J Jakubowiak, Philip L McCarthy, et al.
Leukemia & Lymphoma|October 3, 2025
Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX studyNizar J Bahlis, Jeffrey Zonder, Lionel Karlin, et al.
Haematologica|July 11, 2015
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myelomaJesus F San Miguel, Katja C Weisel, Kevin W Song, et al.
The New England Journal of Medicine|August 30, 2008
Bortezomib plus melphalan and prednisone for initial treatment of multiple myelomaJesús F San Miguel, Rudolf Schlag, Nuriet K Khuageva, et al.
European Journal of Haematology|March 4, 2011
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myelomaMichel Delforge, Evangelos Terpos, Paul G Richardson, et al.
British Journal of Haematology|May 29, 2010
Monoclonal gammopathy of undetermined significance: a consensus statementJames R Berenson, Kenneth C Anderson, Robert A Audell, et al.
Blood|July 22, 2016
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myelomaHervé Avet-Loiseau, Rafael Fonseca, David Siegel, et al.
American Journal of Hematology|April 22, 2011
No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 yearsEfstathios Kastritis, Marie-Christine Kyrtsonis, Evdoxia Hatjiharissi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2023
Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's MacroglobulinemiaChristian Buske, Meletios A Dimopoulos, Alexander Grunenberg, et al.
British Journal of Haematology|June 28, 2017
Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trialJesús F San-Miguel, Vania T M Hungria, Sung-Soo Yoon, et al.
Pageof 66